The recent granting of US Patent 12673101 for a novel Varicella zoster invention marks a major milestone in infectious disease prevention. The company that patented this groundbreaking invention is Adjuvance Technologies, Inc., a biopharmaceutical firm dedicated to empowering health through fundamental breakthroughs in vaccine design. By focusing on advanced formulations, the research team has successfully developed new methods to combat the virus responsible for chickenpox and shingles.
Because of this remarkable achievement, the invention won the prestigious Patent of the Month for the Nebraska state for the month of August 2026. Adjuvance Technologies is headquartered in Lincoln, Nebraska, and this recognition highlights the state’s rapidly growing biotechnology sector. The award committee selected this specific patent because it represents a homegrown innovation with a profound global impact on public health, cementing Nebraska’s position as a hub for cutting-edge medical research and development.
Why This Varicella Zoster Invention is So Innovative
The core innovation of this patent lies in the use of next-generation, semi-synthetic saponin adjuvants. Traditional vaccines for Varicella zoster, particularly those aimed at preventing shingles in older adults, often cause high reactogenicity, leading to significant side effects like pain at the injection site, fever, and fatigue. Adjuvance Technologies has engineered a solution that fundamentally alters this dynamic. By utilizing their novel adjuvant technology, this invention drastically improves the body’s immune response to the vaccine antigens while showing virtually no detectable reactogenicity. This means patients can receive highly effective protection against Varicella zoster without suffering from the debilitating side effects commonly associated with current options.
Eligibility for the US R&D Tax Credit
The practical applications of this patent provide an excellent pathway to be eligible for the Research and Development (R&D) tax credit in the USA. To qualify, a company must engage in activities that resolve technological uncertainty through a process of experimentation. For this Varicella zoster vaccine, practical applications include synthesizing the complex adjuvant compounds, conducting iterative laboratory testing to optimize the formulation, and running clinical trials to measure both safety and immune response. The financial investments required for these activities, including the wages of scientists, costs of laboratory supplies, and expenses paid to third-party testing facilities, directly align with the IRS criteria for qualified research expenses. By continuously experimenting to eliminate side effects while boosting vaccine efficacy, biotech companies applying these patented methods can significantly reduce their tax liabilities, allowing them to reinvest those savings into further medical breakthroughs.
